Author(s): Marin, Jose J.G. ; Macias, Rócio I.R. ; Asensio, Maitane ; Romero, Marta R. ; Temprano, Alvaro G. ; Pereira, Olívia R. ; Jimenez, Silvia ; Mauriz, Jose Luis ; Di Giacomo, Silvia ; Avila, Matias A. ; Efferth, Thomas ; Briz, Oscar
Date: 2024
Persistent ID: http://hdl.handle.net/10198/30051
Origin: Biblioteca Digital do IPB
Subject(s): ABC proteins; Chemoresistance; Cholangiocarcinoma; Hepatocellular carcinoma; Multidrug resistance
In contrast to other types of cancers, there is no available efficient pharmacological treatment to improve the outcomes of patients suffering from major primary liver cancers, i.e., hepatocellular carcinoma and cholangiocarcinoma. This dismal situation is partly due to the existence in these tumors of many different and synergistic mechanisms of resistance, accounting for the lack of response of these patients, not only to classical chemotherapy but also to more modern pharmacological agents based on the inhibition of tyrosine kinase receptors (TKIs) and the stimulation of the immune response against the tumor using immune checkpoint inhibitors (ICIs). This review summarizes the effort to develop strategies to overcome this severe limitation, including searching for novel drugs derived from synthetic, semisynthetic, or natural products with vectorial properties against therapeutic targets to increase drug uptake or reduce drug export from cancer cells. Besides, immunotherapy is a promising line of research that is already starting to be implemented in clinical practice. Although less successful than in other cancers, the foreseen future for this strategy in treating liver cancers is considerable. Similarly, the pharmacological inhibition of epigenetic targets is highly promising. Many novel "epidrugs", able to act on "writer", "reader" and "eraser" epigenetic players, are currently being evaluated in preclinical and clinical studies. Finally, gene therapy is a broad field of research in the fight against liver cancer chemoresistance, based on the impressive advances recently achieved in gene manipulation. In sum, although the present is still dismal, there is reason for hope in the non-too-distant future.
